Payment overview · 2025
General Payments
$984.39
56 reported records · 20 companies
Healthcare provider profile · identity verified
Puja Patel, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · HILLSBOROUGH, NJ · NPI 1629451034
Verified facts
What the public records show
CMS Open Payments records show Puja Patel, M.D. received $984.39 in general payments during 2025 across 56 reported records.
Novo Nordisk Inc accounted for 18.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 30 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $177.80 | 18.1% | 11 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $98.80 | 10.0% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $96.79 | 9.8% | 6 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $95.32 | 9.7% | 6 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $83.99 | 8.5% | 5 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $59.61 | 6.1% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $53.56 | 5.4% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $51.58 | 5.2% | 3 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $49.40 | 5.0% | 3 | 2025 |
| Medinc of Texas | Unresolved — no canonical attribution shown | $43.53 | 4.4% | 1 | 2025 |
| Aurinia Pharma U.S., Inc. | Unresolved — no canonical attribution shown | $25.77 | 2.6% | 1 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $18.34 | 1.9% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $18.14 | 1.8% | 1 | 2025 |
| IDORSIA PHARMACEUTICALS US INC | Unresolved — no canonical attribution shown | $17.75 | 1.8% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $17.41 | 1.8% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $17.15 | 1.7% | 1 | 2025 |
| ARS Pharmaceuticals Operations, Inc. | Unresolved — no canonical attribution shown | $16.33 | 1.7% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $15.26 | 1.6% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $14.08 | 1.4% | 1 | 2025 |
| Bausch Health US, LLC | Unresolved — no canonical attribution shown | $13.78 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $984.39 | 56 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $105.51 | 7 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $98.80 | 6 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $83.99 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $72.29 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $72.29 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $65.39 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $63.66 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $59.61 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $59.18 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $53.56 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $51.58 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $51.58 | 3 | 2025 |
Source payment records
|
|||||
| Bimzelx Normalized: bimzelx |
Biological | UCB, Inc. | $49.40 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $46.04 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $37.95 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $36.14 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $31.40 | 2 | 2025 |
Source payment records
|
|||||
| LUPKYNIS Normalized: lupkynis |
Drug | Aurinia Pharma U.S., Inc. | $25.77 | 1 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $18.34 | 1 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $18.34 | 1 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $18.34 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $18.14 | 1 | 2025 |
Source payment records
|
|||||
| Quviviq Normalized: quviviq |
Drug | IDORSIA PHARMACEUTICALS US INC | $17.75 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $17.41 | 1 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION | $17.15 | 1 | 2025 |
Source payment records
|
|||||
| NEFFY Normalized: neffy |
Drug | ARS Pharmaceuticals Operations, Inc. | $16.33 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.53 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $15.26 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $14.08 | 1 | 2025 |
Source payment records
|
|||||
| WELLBUTRIN Normalized: wellbutrin |
Drug | Bausch Health US, LLC | $13.78 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
65 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 220 | 73 |
| Amlodipine Besylate | Amlodipine Besylate | 181 | 55 |
| Levothyroxine Sodium | Levothyroxine Sodium | 179 | 53 |
| Metformin Hcl | Metformin Hcl | 116 | 40 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 113 | 42 |
| Omeprazole | Omeprazole | 104 | 42 |
| Hydrochlorothiazide | Hydrochlorothiazide | 91 | 35 |
| Simvastatin | Simvastatin | 88 | 27 |
| Metoprolol Succinate | Metoprolol Succinate | 86 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 77 | 51 |
| Alprazolam | Alprazolam | 74 | 21 |
| Losartan Potassium | Losartan Potassium | 72 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 67 | 18 |
| Synthroid | Levothyroxine Sodium | 65 | 20 |
| Pantoprazole Sodium | Pantoprazole Sodium | 64 | 20 |
| Azithromycin | Azithromycin | 62 | 54 |
| Lisinopril | Lisinopril | 60 | 20 |
| Montelukast Sodium | Montelukast Sodium | 58 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 54 | 23 |
| Gabapentin | Gabapentin | 52 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 49 | 15 |
| Tramadol Hcl | Tramadol Hcl | 49 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 45 | 11 |
| Prednisone | Prednisone | 42 | 27 |
| Trazodone Hcl | Trazodone Hcl | 42 | 15 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 41 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 40 | 11 |
| Sertraline Hcl | Sertraline Hcl | 40 | 13 |
| Famotidine | Famotidine | 35 | 16 |
| Meloxicam | Meloxicam | 35 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 34 | 15 |
| Metformin Hcl Er | Metformin Hcl | 34 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 31 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 29 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 29 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 29 | suppressed |
| Bupropion Xl | Bupropion Hcl | 27 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 27 | suppressed |
| Furosemide | Furosemide | 25 | 13 |
| Temazepam | Temazepam | 25 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 24 | suppressed |
| Glimepiride | Glimepiride | 24 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 20 |
| Atenolol | Atenolol | 22 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 21 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 19 |
| Doxycycline Hyclate | Doxycycline Hyclate | 20 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Mupirocin | Mupirocin | 20 | 17 |
| Diazepam | Diazepam | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | 16 |
| Amoxicillin | Amoxicillin | 17 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 17 | suppressed |
| Celecoxib | Celecoxib | 16 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 16 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 16 | 15 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Cephalexin | Cephalexin | 15 | 14 |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Lorazepam | Lorazepam | 15 | suppressed |
| Nystatin | Nystatin | 15 | 11 |
| Acyclovir | Acyclovir | 14 | suppressed |
| Ambien Cr | Zolpidem Tartrate | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Allopurinol | Allopurinol | 13 | suppressed |
| Eliquis | Apixaban | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Jardiance | Empagliflozin | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Ozempic | Semaglutide | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Carvedilol | Carvedilol | 11 | suppressed |
| Clonazepam | Clonazepam | 11 | 11 |
| Ezetimibe | Ezetimibe | 11 | suppressed |
| Norethindrone-E.Estradiol-Iron | Norethindrone-E.Estradiol-Iron | 11 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $984.39 · 56 records | Novo Nordisk Inc | AIRSUPRA, Bimzelx, CAPLYTA, CONTRAVE, Cologuard Collection Kit, DUPIXENT, ELIQUIS, FARXIGA, Flector, KISUNLA, LUPKYNIS, Licart, MOUNJARO, NEFFY, NURTEC ODT, OTEZLA, Ohtuvayre, Ozempic, QULIPTA, Quviviq, REPATHA, REXULTI, Rybelsus, Tirosint, UBRELVY, WELLBUTRIN, Wegovy, ZAVZPRET, ZEPBOUND, ZORYVE | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error